Trials / Completed
CompletedNCT00163046
A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-day, Polysomnographic Study of Gabapentin 250 mg in Transient Insomnia Induced by a Sleep Phase Advance
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 256 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to to assess the effect of gabapentin compared to placebo on sleep, using polysomnography along with subjective sleep assessments, in subjects with transient insomnia induced by a sleep phase advance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gabapentin | Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days |
| DRUG | Placebo | Matched placebo 30 minutes prior to bedtime for 28 days |
Timeline
- Start date
- 2005-10-01
- Completion
- 2006-04-01
- First posted
- 2005-09-13
- Last updated
- 2021-02-02
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00163046. Inclusion in this directory is not an endorsement.